A patient with stable COPD receives prescriptions for an inhaled glucocorticoid and an inhaled beta2-adrenergic agonist. Which statement indicates understanding of this medication regimen?

• A. The glucocorticoid is used as prophylaxis to prevent exacerbations.
• B. The glucocorticoid is used PRN to treat acute attacks.
• C. The beta2-adrenergic agonist should be used daily to prevent symptoms.
• D. The beta2-adrenergic agonist drugs should not be used daily; they are used to treat symptoms as needed.

Answer: (A)

Inhaled corticosteroids in COPD are used to reduce airway inflammation and lower the risk of exacerbations over time. They are a maintenance, preventive therapy rather than a rescue treatment for an acute flare. That’s why saying the glucocorticoid is used prophylactically to prevent exacerbations best reflects its role in a stable COPD regimen.

The inhaled beta2-adrenergic agonist provides bronchodilation. If it’s the long-acting type, it’s taken daily to prevent symptoms as part of maintenance therapy; if it’s the short-acting type, it’s used as needed for quick relief. The key point is that the anti-inflammatory agent is aimed at preventing exacerbations, while the bronchodilator’s role is to keep airways open, with the maintenance vs rescue distinction depending on which beta2-agonist is prescribed.

The other statements don’t fit typical COPD management: inhaled corticosteroids aren’t used PRN for acute attacks, and daily maintenance use of a beta2-agonist is common when a long-acting agent is involved, rather than using it only as needed.